Your browser doesn't support javascript.
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
Beddingfield, Brandon J; Iwanaga, Naoki; Chapagain, Prem P; Zheng, Wenshu; Roy, Chad J; Hu, Tony Y; Kolls, Jay K; Bix, Gregory J.
  • Beddingfield BJ; Division of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Iwanaga N; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Chapagain PP; Departments of Pediatrics and Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Zheng W; Department of Physics, Florida International University, Miami, Florida, USA.
  • Roy CJ; Biomolecular Sciences Institute, Florida International University, Miami, Florida, USA.
  • Hu TY; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Kolls JK; Division of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Bix GJ; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
JACC Basic Transl Sci ; 6(1): 1-8, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-866798
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5ß1 integrin-based mechanism and indicates that inhibiting the spike protein interaction with α5ß1 integrin (+/- ACE2) and the interaction between α5ß1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: JACC Basic Transl Sci Year: 2021 Document Type: Article Affiliation country: J.jacbts.2020.10.003

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: JACC Basic Transl Sci Year: 2021 Document Type: Article Affiliation country: J.jacbts.2020.10.003